Matches in SemOpenAlex for { <https://semopenalex.org/work/W3109129325> ?p ?o ?g. }
Showing items 1 to 88 of
88
with 100 items per page.
- W3109129325 endingPage "S1310" @default.
- W3109129325 startingPage "S1310" @default.
- W3109129325 abstract "Based on the phase III REFLECT study, lenvatinib (LEN) has been recommended as a first-line (1L) therapy for uHCC since 2018. Recent years have seen a further expansion of 1L treatment recommendations for uHCC, to include atezolizumab+bevacizumab, nivolumab, FOLFOX4 and donafenib. We conducted a network meta-analysis (NMA) to compare the efficacy and safety of lenvatinib with other systemic therapies in first-line uHCC. A systematic literature review identified randomized, controlled, multicenter trials in adults with advanced HCC who had received no prior systemic therapy. Literature retrieval was conducted using PubMed, ScienceDirect, the Cochrane Database, EMBASE and other sources. Objective response rate (ORR), disease progression-free survival (PFS), time-to-progression (TTP) and treatment discontinuations due to adverse events (AEs) were extracted from published studies and quantitatively pooled using frequentist NMA. Pairwise risk ratio(RR), hazard ratio(HR) with confidence interval was calculated. The P-scores were used to rank each treatment. In total, 1398 records were screened and 27 were eligible for analysis, and the treatments included were atezolizumab+bevacizumab, brivanib, FOLFOX4, donafenib, dovitinib, lenvatinib, linifanib, nintedanib, nivolumab, sorafenib, sunitinib, vandetanib, 11 sorafenib combination therapies and three other combination therapies. For ORR and TTP, lenvatinib was ranked first (P-scores: 0.88 and 0.99), for PFS, atezolizumab+bevacizumab was ranked first followed by lenvatinib (HR: 0.89; 95% CI, 0.64-1.25; P-scores: 0.95 and 0.90) and donafinib and nivolumab ranked 5th and 6th (HR: 1.38; 95% CI, 1.09-1.73, HR: 1.41; 95% CI, 1.13-1.76; P scores: 0.90 vs 0.59 vs 0.56 respectively). Atezolizumab+bevacizumab was associated with the highest probability of discontinuation due to AEs (RR: 1.27 [0.35-4.60]), lenvatinib ranked 4th (P scores: 0.25 and 0.39, respectively). This NMA suggested that greater ORR and TTP benefits with first-line use of Lenvatinib than others. Although Atezolizumab+Bevacizumab showed more benefit in PFS, more discontinuation because of AE should also take into consideration." @default.
- W3109129325 created "2020-12-07" @default.
- W3109129325 creator A5011835067 @default.
- W3109129325 creator A5035609529 @default.
- W3109129325 creator A5060029428 @default.
- W3109129325 creator A5069047498 @default.
- W3109129325 creator A5082301281 @default.
- W3109129325 creator A5083853234 @default.
- W3109129325 date "2020-11-01" @default.
- W3109129325 modified "2023-10-16" @default.
- W3109129325 title "181P Evaluation of first-line systemic treatments for unresectable hepatocellular carcinoma (uHCC): A network meta-analysis" @default.
- W3109129325 doi "https://doi.org/10.1016/j.annonc.2020.10.202" @default.
- W3109129325 hasPublicationYear "2020" @default.
- W3109129325 type Work @default.
- W3109129325 sameAs 3109129325 @default.
- W3109129325 citedByCount "0" @default.
- W3109129325 crossrefType "journal-article" @default.
- W3109129325 hasAuthorship W3109129325A5011835067 @default.
- W3109129325 hasAuthorship W3109129325A5035609529 @default.
- W3109129325 hasAuthorship W3109129325A5060029428 @default.
- W3109129325 hasAuthorship W3109129325A5069047498 @default.
- W3109129325 hasAuthorship W3109129325A5082301281 @default.
- W3109129325 hasAuthorship W3109129325A5083853234 @default.
- W3109129325 hasBestOaLocation W31091293251 @default.
- W3109129325 hasConcept C121608353 @default.
- W3109129325 hasConcept C126322002 @default.
- W3109129325 hasConcept C143998085 @default.
- W3109129325 hasConcept C197934379 @default.
- W3109129325 hasConcept C207103383 @default.
- W3109129325 hasConcept C2775949291 @default.
- W3109129325 hasConcept C2776264508 @default.
- W3109129325 hasConcept C2776694085 @default.
- W3109129325 hasConcept C2777701055 @default.
- W3109129325 hasConcept C2777714996 @default.
- W3109129325 hasConcept C2777802072 @default.
- W3109129325 hasConcept C2778019345 @default.
- W3109129325 hasConcept C2778341716 @default.
- W3109129325 hasConcept C2778695046 @default.
- W3109129325 hasConcept C2779490328 @default.
- W3109129325 hasConcept C2779551604 @default.
- W3109129325 hasConcept C2780030458 @default.
- W3109129325 hasConcept C2780171596 @default.
- W3109129325 hasConcept C2780333294 @default.
- W3109129325 hasConcept C2780739268 @default.
- W3109129325 hasConcept C44249647 @default.
- W3109129325 hasConcept C71924100 @default.
- W3109129325 hasConceptScore W3109129325C121608353 @default.
- W3109129325 hasConceptScore W3109129325C126322002 @default.
- W3109129325 hasConceptScore W3109129325C143998085 @default.
- W3109129325 hasConceptScore W3109129325C197934379 @default.
- W3109129325 hasConceptScore W3109129325C207103383 @default.
- W3109129325 hasConceptScore W3109129325C2775949291 @default.
- W3109129325 hasConceptScore W3109129325C2776264508 @default.
- W3109129325 hasConceptScore W3109129325C2776694085 @default.
- W3109129325 hasConceptScore W3109129325C2777701055 @default.
- W3109129325 hasConceptScore W3109129325C2777714996 @default.
- W3109129325 hasConceptScore W3109129325C2777802072 @default.
- W3109129325 hasConceptScore W3109129325C2778019345 @default.
- W3109129325 hasConceptScore W3109129325C2778341716 @default.
- W3109129325 hasConceptScore W3109129325C2778695046 @default.
- W3109129325 hasConceptScore W3109129325C2779490328 @default.
- W3109129325 hasConceptScore W3109129325C2779551604 @default.
- W3109129325 hasConceptScore W3109129325C2780030458 @default.
- W3109129325 hasConceptScore W3109129325C2780171596 @default.
- W3109129325 hasConceptScore W3109129325C2780333294 @default.
- W3109129325 hasConceptScore W3109129325C2780739268 @default.
- W3109129325 hasConceptScore W3109129325C44249647 @default.
- W3109129325 hasConceptScore W3109129325C71924100 @default.
- W3109129325 hasLocation W31091293251 @default.
- W3109129325 hasOpenAccess W3109129325 @default.
- W3109129325 hasPrimaryLocation W31091293251 @default.
- W3109129325 hasRelatedWork W2757581310 @default.
- W3109129325 hasRelatedWork W3084251940 @default.
- W3109129325 hasRelatedWork W3086685948 @default.
- W3109129325 hasRelatedWork W3150298243 @default.
- W3109129325 hasRelatedWork W3172475080 @default.
- W3109129325 hasRelatedWork W3192554530 @default.
- W3109129325 hasRelatedWork W3198492474 @default.
- W3109129325 hasRelatedWork W4281682363 @default.
- W3109129325 hasRelatedWork W4283820829 @default.
- W3109129325 hasRelatedWork W4317892000 @default.
- W3109129325 hasVolume "31" @default.
- W3109129325 isParatext "false" @default.
- W3109129325 isRetracted "false" @default.
- W3109129325 magId "3109129325" @default.
- W3109129325 workType "article" @default.